In early-stage CKD with metabolic syndrome and macroalbuminuria, GLP-1 RAs are particularly helpful because of their weight-loss and anti-inflammatory properties, which can further reduce renal risk. This evidence concerns the gene GLP1R and metabolic syndrome.